FDA 483 - Pure Source LLC - August 14, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Pure Source LLC, a contract OTC drug manufacturer in Doral, FL, revealed significant deficiencies in its quality system, production controls, and material management. The firm failed to thoroughly investigate discrepancies, properly manage deviations, and adequately qualify component suppliers, with some issues being repeat observations from previous inspections. These findings indicate a concerning lack of adherence to good manufacturing practices.
ID · efbbfd13-7a5b-4a38-9ed4-3df3ce6db000